Compile Data Set for Download or QSAR
Report error Found 214 Enz. Inhib. hit(s) with all data for entry = 12434
TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702472(US20240360148, Example 225)
Affinity DataIC50: 34nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702470(US20240360148, Example 223)
Affinity DataIC50: 52nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702467(US20240360148, Example 220)
Affinity DataIC50: 67nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702395(US20240360148, Example 139)
Affinity DataIC50: 70nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702469(US20240360148, Example 222)
Affinity DataIC50: 100nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702498(US20240360148, Example 251)
Affinity DataIC50: 110nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702383(US20240360148, Example 122)
Affinity DataIC50: 120nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702396(US20240360148, Example 140)
Affinity DataIC50: 120nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702474(US20240360148, Example 227)
Affinity DataIC50: 120nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702464(US20240360148, Example 217)
Affinity DataIC50: 130nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702496(US20240360148, Example 249)
Affinity DataIC50: 140nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702304(US20240360148, Example 21)
Affinity DataIC50: 150nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702478(US20240360148, Example 231)
Affinity DataIC50: 160nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702471(US20240360148, Example 224)
Affinity DataIC50: 172nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702389(US20240360148, Example 132)
Affinity DataIC50: 180nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702403(US20240360148, Example 151)
Affinity DataIC50: 180nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702463(US20240360148, Example 216)
Affinity DataIC50: 180nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702320(US20240360148, Example 46)
Affinity DataIC50: 200nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702287(US20240360148, Example 1)
Affinity DataIC50: 210nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702483(US20240360148, Example 236)
Affinity DataIC50: 240nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702379(US20240360148, Example 118)
Affinity DataIC50: 290nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702381(US20240360148, Example 120)
Affinity DataIC50: 310nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702390(US20240360148, Example 134)
Affinity DataIC50: 320nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702327(US20240360148, Example 53)
Affinity DataIC50: 340nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702468(US20240360148, Example 221)
Affinity DataIC50: 347nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702397(US20240360148, Example 141)
Affinity DataIC50: 350nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702393(US20240360148, Example 137)
Affinity DataIC50: 360nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702305(US20240360148, Example 22)
Affinity DataIC50: 390nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702499(US20240360148, Example 252)
Affinity DataIC50: 390nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702354(US20240360148, Example 92)
Affinity DataIC50: 400nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702382(US20240360148, Example 121)
Affinity DataIC50: 430nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702380(US20240360148, Example 119)
Affinity DataIC50: 440nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702394(US20240360148, Example 138)
Affinity DataIC50: 500nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702388(US20240360148, Example 129)
Affinity DataIC50: 505nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702324(US20240360148, Example 50)
Affinity DataIC50: 510nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702391(US20240360148, Example 135)
Affinity DataIC50: 510nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702399(US20240360148, Example 144)
Affinity DataIC50: 540nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702328(US20240360148, Example 54)
Affinity DataIC50: 550nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702402(US20240360148, Example 147)
Affinity DataIC50: 620nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702303(US20240360148, Example 20)
Affinity DataIC50: 690nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702326(US20240360148, Example 52)
Affinity DataIC50: 690nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702387(US20240360148, Example 128)
Affinity DataIC50: 750nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702345(US20240360148, Example 83)
Affinity DataIC50: 760nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702355(US20240360148, Example 93)
Affinity DataIC50: 760nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702373(US20240360148, Example 112)
Affinity DataIC50: 760nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702497(US20240360148, Example 250)
Affinity DataIC50: 760nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702368(US20240360148, Example 106)
Affinity DataIC50: 800nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702465(US20240360148, Example 218)
Affinity DataIC50: 810nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702487(US20240360148, Example 240)
Affinity DataIC50: 810nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

TargetSUMO-activating enzyme subunit 1(Human)
Suvalent Therapeutics

US Patent
LigandPNGBDBM702495(US20240360148, Example 248)
Affinity DataIC50: 970nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2025
Entry Details
Go to US Patent

Displayed 1 to 50 (of 214 total ) | Next | Last >>
Jump to: